In metastatic melanoma, a well-characterized predictive biomarker of response guiding the therapeutic decision process is the BRAF V600 mutation, which is somehow predictive of response to BRAF ± MEK inhibition with low rates of primary resistance [53,54,55]. This evidence concerns the gene MAP2K7 and metastatic melanoma.